Holtkamp, Martin
Breuer, Eva
Gaus, Verena
Lehmann, Rebekka
Siebert, Eberhard
Steinbart, David
Vorderwülbecke, Bernd
Article History
Accepted: 16 March 2022
First Online: 4 November 2022
Declarations
:
: M. Holtkamp: Between 2018 and 2022, M. Holtkamp received honoraria for consulting and lectures from Angelini/Arvelle, Bial, Desitin, Eisai, GW Pharma, UCB, and Zogenix. There is no connection to the contents of this article. M. Holtkamp is coordinator of the guideline group “Management of First Epileptic Seizure and Epilepsies” of the German Society of Neurology. R. Lehmann received honoraria from Eisai. There is no connection to the contents of this article. E. Breuer, V. Gaus, R. Lehmann, E. Siebert, D. Steinbart, and B. Vorderwülbecke declare that they have no competing interests.
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.
: The supplement containing this article is not sponsored by industry.
Free to read: This content has been made available to all.